C-Terminal Bax Peptide Membrane Permeabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and microbial infections face challenges due to drug resistance, particularly in cells expressing high levels of anti-apoptotic proteins like Bcl-2, which inhibit the effectiveness of standard chemotherapeutics and antimicrobial agents.
Innovation Solution
Administration of a C-terminal Bax peptide (CT20p peptide) that permeabilizes cell membranes, forming pores and facilitating ion exchange, leading to cell death, which is independent of endogenous Bax activity and resistant to Bcl-2 overexpression, and can be combined with existing therapies to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapeutics or antimicrobial agents are used, then treatment of disease or infection is achieved, but drug resistance develops due to abnormal expression of anti-apoptotic proteins like Bcl-2
Solution Approach 1:
The invention uses a truncated C-terminal fragment of Bax (residues 173-192) instead of the full-length protein. This segmentation approach isolates the pore-forming domain that is responsible for membrane permeabilization and cell death, separating it from regulatory regions that may be inhibited by anti-apoptotic proteins like Bcl-2. The fragmented peptide maintains cytotoxic activity while overcoming drug resistance mechanisms.
Solution Approach 2:
The invention extracts and utilizes only the essential C-terminal 20 amino acids of Bax that are sufficient to induce membrane permeabilization and cell death. This extracted peptide (CT20p) contains the core functional elements needed for pore formation and ion exchange, removing unnecessary regulatory sequences that could be targeted by resistance mechanisms.
2Stability of the object's composition
If Bcl-2 family anti-apoptotic proteins are overexpressed, then cell survival is enhanced, but pro-apoptotic proteins like Bax are inhibited
Solution Approach 1:
Instead of using the full-length Bax protein that requires translocation from cytosol to mitochondria (a process inhibited by Bcl-2), the invention inverts the approach by directly delivering the C-terminal pore-forming domain to the membrane. This reversed strategy bypasses the need for Bax activation and translocation, directly inducing membrane permeabilization regardless of Bcl-2 levels.
Solution Approach 2:
The C-terminal Bax peptide acts as an intermediary that directly interacts with mitochondrial membranes to form pores, bypassing the need for interaction with anti-apoptotic proteins. This mediator approach allows the peptide to directly induce cell death without being blocked by Bcl-2 or other regulatory proteins in the apoptotic pathway.
3Object-affected harmful factors
If full-length Bax protein is used, then pro-apoptotic activity is achieved, but the process is complex and requires mitochondrial translocation
Solution Approach 1:
The invention extracts only the essential C-terminal 20 amino acids of Bax that are sufficient to induce membrane permeabilization and cell death. This extracted peptide (CT20p) contains the core functional elements needed for pore formation and ion exchange, removing unnecessary regulatory sequences that complicate the mechanism.
Solution Approach 2:
The invention changes the molecular parameters by using a truncated peptide version of Bax instead of the full-length protein. This parameter change reduces molecular weight and structural complexity while maintaining the essential pore-forming function. The simplified peptide can directly interact with membranes without requiring the complex translocation process of the full-length protein.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CT20p peptide effectively induces cell death in cancer and microbial cells, overcoming drug resistance mechanisms and sensitizing cells to treatment, thereby improving treatment outcomes for cancer and infectious diseases.
Implementation Method 1
forming at least one pore in a membrane of at least one cell, wherein the peptide or a composition comprising an effective amount of a CT20p peptide destabilizes at least one membrane, facilitates ion exchange, and/or causes a sequestered molecule to be released
Data Source
AI summary
In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.